Tegeo oral treatment for advanced gastric cancer has been used in Japan for more than 10 years. This drug has now entered China. However, it is not well known by either medical personnel or patients. And Xirodar (Capecitabine) is also a good drug for oral treatment of advanced gastric cancer, what are the similarities and differences between them? 1. Both are oral drugs with similar therapeutic effects as 5-fluorouracil (5-FU) intravenous chemotherapy. 2. Both are drugs preferentially activated within the tumor (selective intra-tumor activation), with higher concentrations of the drug within the tumor and in the plasma. 3. Both are very expensive. The differences between Siroda and Tegeo: 1. Different ingredients: Siroda, also known as Capecitabine, has only one ingredient, chemically named N4-pentacarbonyldeoxy-5-fluorocytidine, a fluoropyrimidine deoxyriboside carbamate. As an oral drug, Siroda mimics continuous intravenous 5-FU. tegeo, is an improved formulation of the antineoplastic agent tegafur. In addition to this active ingredient, it contains two substances used to modulate the biological effects of the drug: gemestrol and potassium oxyzincate, also known as potassium otilacid, which are compounded in a molar ratio of 1:0.4:1 in that order. 2. The mechanism of action of Siroda and Tegeo is different (1) After oral administration, Siroda is rapidly absorbed by the intestinal tract as an intact molecule through the intestinal mucosa, and then rapidly transformed into 5-FU at the tumor site through the tertiary enzyme chain reaction, and its content in tumor tissues is significantly higher than that of normal tissues, which minimizes the damage of 5-FU to normal human cells. Siroda (capecitabine) has high antitumor activity in a large number of humans including some 5-FU-resistant solid tumor transplant models. (2) Tegeo, of which tegafur (FT) is a precursor drug of 5-Fu, has excellent oral bioavailability and can be converted to 5-Fu in vivo; Gemostat inhibits the breakdown of 5-Fu and enhances antitumor activity; potassium oxyzincate reduces the toxicity and adverse effects of 5-Fu in the gastrointestinal tract. Tegeo capsules composed of these two biochemical regulators function to enable patients to obtain higher 5-FU blood concentration in their bodies, which improves the anti-cancer activity and reduces the gastrointestinal toxicity of the drug. 3. The application scope of Herodal and Tegeo is different. Herodal is mainly used for breast cancer and colorectal cancer, but can also be used for other tumors. According to the data, it also has good effect for advanced gastric cancer and cardia cancer. Currently, Beijing has included Siroda for advanced breast and colorectal cancer in its health insurance coverage. Tegeo is currently approved in Japan for the treatment of advanced gastric cancer, head and neck cancer, rectal cancer, non-small cell lung cancer, metastatic breast cancer and pancreatic cancer, and other seven types of oncological diseases, and has become the first-line drug for the treatment of advanced gastric cancer in Japan. The first approved indication in China is unresectable locally advanced or metastatic gastric cancer, which is not yet covered by national health insurance. Strictly speaking, neither Siroda nor Tegeo are molecularly targeted therapeutics, but rather selective intra-tumor activation drugs.